Loading...

Mark Moasser, MD

TitleProfessor
InstitutionUniversity of California San Francisco
DepartmentMedicine
Address2340 Sutter Street
San Francisco CA 94115
Phone415-353-7070
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    Tufts UniversityM.D.1988School of Medicine

    Collapse Research 
    Collapse Research Activities and Funding
    Pilot studies to develop probes for in vivo imaging of P13K/Akt pathway activity
    NIH/NCI R21CA121108Jan 1, 2007 - Dec 31, 2009
    Role: Principal Investigator
    Understanding resistance in the HER2-HER3 tumor drive
    NIH/NCI R01CA122216Jul 1, 2006 - May 31, 2018
    Role: Principal Investigator
    Adhesion signaling by a novel mitotic substrate of src
    NIH/NCI R01CA113952Apr 1, 2005 - Feb 28, 2011
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Ruiz-Saenz A, Dreyer C, Campbell MR, Steri V, Gulizia NP, Moasser M. HER2 amplification in tumors activates PI3K/Akt signaling independent of HER3. Cancer Res. 2018 May 14. PMID: 29760043.
      View in: PubMed
    2. Pollan SG, Huang F, Sperger JM, Lang JM, Morrissey C, Cress AE, Chu CY, Bhowmick NA, You S, Freeman MR, Spassov DS, Moasser M, Carter WG, Satapathy SR, Shah K, Knudsen BS. Regulation of inside-out ß1-integrin activation by CDCP1. Oncogene. 2018 Mar 07. PMID: 29511352.
      View in: PubMed
    3. Ruiz-Saenz A, Moasser M. Targeting HER2 by Combination Therapies. J Clin Oncol. 2018 Mar 10; 36(8):808-811. PMID: 29381433.
      View in: PubMed
    4. Dhawan MS, Bartelink IH, Aggarwal RR, Leng J, Zhang JZ, Pawlowska N, Terranova-Barberio M, Grabowsky JA, Gewitz A, Chien AJ, Moasser M, Kelley RK, Maktabi T, Thomas S, Munster PN. Differential Toxicity in Patients with and without DNA Repair Mutations: Phase I Study of Carboplatin and Talazoparib in Advanced Solid Tumors. Clin Cancer Res. 2017 Nov 01; 23(21):6400-6410. PMID: 28790114.
      View in: PubMed
    5. Enyindah-Asonye G, Li Y, Ruth JH, Spassov DS, Hebron KE, Zijlstra A, Moasser M, Wang B, Singer NG, Cui H, Ohara RA, Rasmussen SM, Fox DA, Lin F. CD318 is a ligand for CD6. Proc Natl Acad Sci U S A. 2017 Aug 15; 114(33):E6912-E6921. PMID: 28760953.
      View in: PubMed
    6. Littlefield P, Moasser M, Jura N. Retraction Notice to: An ATP-Competitive Inhibitor Modulates the Allosteric Function of the HER3 Pseudokinase. Cell Chem Biol. 2017 07 20; 24(7):917. PMID: 28732202.
      View in: PubMed
    7. Chien AJ, Cockerill A, Fancourt C, Schmidt E, Moasser M, Rugo HS, Melisko ME, Ko AH, Kelley RK, Korn WM, Esserman LJ, van't Veer L, Yau C, Wolf DM, Munster PN. A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies. Breast Cancer Res Treat. 2016 Feb; 155(3):521-30. PMID: 26875185.
      View in: PubMed
    8. Campbell MR, Zhang H, Ziaee S, Ruiz-Saenz A, Gulizia N, Oeffinger J, Amin DN, Ahuja D, Moasser M, Park CC. Effective treatment of HER2-amplified breast cancer by targeting HER3 and ß1 integrin. Breast Cancer Res Treat. 2016 Feb; 155(3):431-40. PMID: 26860947; PMCID: PMC4767608 [Available on 02/09/17].
    9. Amin DN, Ruiz-Saenz A, Gulizia N, Moasser M. Chemical probing of HER2-amplified cancer cells identifies TORC2 as a particularly effective secondary target for combination with lapatinib. Oncotarget. 2015 Dec 01; 6(38):41123-33. PMID: 26516700; PMCID: PMC4747394.
    10. Moasser M, Krop IE. The Evolving Landscape of HER2 Targeting in Breast Cancer. JAMA Oncol. 2015 Nov; 1(8):1154-61. PMID: 26204261.
      View in: PubMed
    11. Amin DN, Ahuja D, Yaswen P, Moasser M. A TORC2-Akt Feed-Forward Topology Underlies HER3 Resiliency in HER2-Amplified Cancers. Mol Cancer Ther. 2015 Dec; 14(12):2805-17. PMID: 26438156; PMCID: PMC4674361 [Available on 12/01/16].
    12. Chang YH, Korkola J, Amin DN, Moasser M, Carmena JM, Gray JW, Tomlin CJ. Disentangling multidimensional spatio-temporal data into their common and aberrant responses. PLoS One. 2015; 10(4):e0121607. PMID: 25901353; PMCID: PMC4406848.
    13. Campbell MR, Moasser M. HER Targeting in HER2-Negative Breast Cancers: Looking for the HER3 Positive. Clin Cancer Res. 2015 Jul 01; 21(13):2886-8. PMID: 25609069; PMCID: PMC4490014.
    14. Masters GA, Krilov L, Bailey HH, Brose MS, Burstein H, Diller LR, Dizon DS, Fine HA, Kalemkerian GP, Moasser M, Neuss MN, O'Day SJ, Odenike O, Ryan CJ, Schilsky RL, Schwartz GK, Venook AP, Wong SL, Patel JD. Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol. 2015 Mar 01; 33(7):786-809. PMID: 25605863.
      View in: PubMed
    15. Hiatt RA, Porco TC, Liu F, Balke K, Balmain A, Barlow J, Braithwaite D, Diez-Roux AV, Kushi LH, Moasser M, Werb Z, Windham GC, Rehkopf DH. A multilevel model of postmenopausal breast cancer incidence. Cancer Epidemiol Biomarkers Prev. 2014 Oct; 23(10):2078-92. PMID: 25017248.
      View in: PubMed
    16. Moasser M. Two dimensions in targeting HER2. J Clin Oncol. 2014 Jul 01; 32(19):2074-7. PMID: 24868026; PMCID: PMC4517047.
    17. Chien AJ, Munster PN, Melisko ME, Rugo HS, Park JW, Goga A, Auerback G, Khanafshar E, Ordovas K, Koch KM, Moasser M. Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer. J Clin Oncol. 2014 May 10; 32(14):1472-9. PMID: 24711549; PMCID: PMC4017711.
    18. Littlefield P, Moasser M, Jura N. RETRACTED: An ATP-competitive inhibitor modulates the allosteric function of the HER3 pseudokinase. Chem Biol. 2014 04 24; 21(4):453-458. PMID: 24656791; PMCID: PMC4018233.
    19. Spassov DS, Wong CH, Wong SY, Reiter JF, Moasser M. Trask loss enhances tumorigenic growth by liberating integrin signaling and growth factor receptor cross-talk in unanchored cells. Cancer Res. 2013 Feb 01; 73(3):1168-79. PMID: 23243018; PMCID: PMC3563920.
    20. Amin DN, Sergina N, Lim L, Goga A, Moasser M. HER3 signalling is regulated through a multitude of redundant mechanisms in HER2-driven tumour cells. Biochem J. 2012 Nov 01; 447(3):417-25. PMID: 22853430; PMCID: PMC3722874.
    21. Spassov DS, Ahuja D, Wong CH, Moasser M. The structural features of Trask that mediate its anti-adhesive functions. PLoS One. 2011 Apr 29; 6(4):e19154. PMID: 21559459; PMCID: PMC3084758.
    22. Spassov DS, Wong CH, Moasser M. Trask phosphorylation defines the reverse mode of a phosphotyrosine signaling switch that underlies cell anchorage state. Cell Cycle. 2011 Apr 15; 10(8):1225-32. PMID: 21490433; PMCID: PMC3117134.
    23. McArthur HL, Rugo H, Nulsen B, Hawks L, Grothusen J, Melisko M, Moasser M, Paulson M, Traina T, Patil S, Zhou Q, Steingart R, Dang C, Morrow M, Cordeiro P, Fornier M, Park J, Seidman A, Lake D, Gilewski T, Theodoulou M, Modi S, D'Andrea G, Sklarin N, Robson M, Moynahan ME, Sugarman S, Sealey JE, Laragh JH, Merali C, Norton L, Hudis CA, Dickler MN. A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancer. Clin Cancer Res. 2011 May 15; 17(10):3398-407. PMID: 21350003; PMCID: PMC4994894.
    24. Spassov DS, Wong CH, Sergina N, Ahuja D, Fried M, Sheppard D, Moasser M. Phosphorylation of Trask by Src kinases inhibits integrin clustering and functions in exclusion with focal adhesion signaling. Mol Cell Biol. 2011 Feb; 31(4):766-82. PMID: 21189288; PMCID: PMC3028653.
    25. Amin DN, Campbell MR, Moasser M. The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics. Semin Cell Dev Biol. 2010 Dec; 21(9):944-50. PMID: 20816829; PMCID: PMC2991618.
    26. Campbell MR, Amin D, Moasser M. HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy. Clin Cancer Res. 2010 Mar 01; 16(5):1373-83. PMID: 20179223; PMCID: PMC2831167.
    27. Amin DN, Sergina N, Ahuja D, McMahon M, Blair JA, Wang D, Hann B, Koch KM, Shokat KM, Moasser M. Resiliency and vulnerability in the HER2-HER3 tumorigenic driver. Sci Transl Med. 2010 Jan 27; 2(16):16ra7. PMID: 20371474; PMCID: PMC3033659.
    28. Chien AJ, Illi JA, Ko AH, Korn WM, Fong L, Chen LM, Kashani-Sabet M, Ryan CJ, Rosenberg JE, Dubey S, Small EJ, Jahan TM, Hylton NM, Yeh BM, Huang Y, Koch KM, Moasser M. A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound Paclitaxel for advanced solid malignancies. Clin Cancer Res. 2009 Sep 01; 15(17):5569-75. PMID: 19706807; PMCID: PMC3029022.
    29. Spassov DS, Baehner FL, Wong CH, McDonough S, Moasser M. The transmembrane src substrate Trask is an epithelial protein that signals during anchorage deprivation. Am J Pathol. 2009 May; 174(5):1756-65. PMID: 19349359; PMCID: PMC2671264.
    30. Wong CH, Baehner FL, Spassov DS, Ahuja D, Wang D, Hann B, Blair J, Shokat K, Welm AL, Moasser M. Phosphorylation of the SRC epithelial substrate Trask is tightly regulated in normal epithelia but widespread in many human epithelial cancers. Clin Cancer Res. 2009 Apr 01; 15(7):2311-22. PMID: 19318475; PMCID: PMC3023342.
    31. Dickler MN, Rugo HS, Eberle CA, Brogi E, Caravelli JF, Panageas KS, Boyd J, Yeh B, Lake DE, Dang CT, Gilewski TA, Bromberg JF, Seidman AD, D'Andrea GM, Moasser M, Melisko M, Park JW, Dancey J, Norton L, Hudis CA. A phase II trial of erlotinib in combination with bevacizumab in patients with metastatic breast cancer. Clin Cancer Res. 2008 Dec 01; 14(23):7878-83. PMID: 19047117.
      View in: PubMed
    32. Arkin M, Moasser M. HER-2-directed, small-molecule antagonists. Curr Opin Investig Drugs. 2008 Dec; 9(12):1264-76. PMID: 19037833; PMCID: PMC3031872.
    33. Torbett NE, Luna-Moran A, Knight ZA, Houk A, Moasser M, Weiss W, Shokat KM, Stokoe D. A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition. Biochem J. 2008 Oct 01; 415(1):97-110. PMID: 18498248; PMCID: PMC3079392.
    34. Chien AJ, Moasser M. Cellular mechanisms of resistance to anthracyclines and taxanes in cancer: intrinsic and acquired. Semin Oncol. 2008 Apr; 35(2 Suppl 2):S1-S14; quiz S39. PMID: 18410794.
      View in: PubMed
    35. Moasser M, Wilmes LJ, Wong CH, Aliu S, Li KL, Wang D, Hom YK, Hann B, Hylton NM. Improved tumor vascular function following high-dose epidermal growth factor receptor tyrosine kinase inhibitor therapy. J Magn Reson Imaging. 2007 Dec; 26(6):1618-25. PMID: 17968965; PMCID: PMC3024590.
    36. Sergina NV, Moasser M. The HER family and cancer: emerging molecular mechanisms and therapeutic targets. Trends Mol Med. 2007 Dec; 13(12):527-34. PMID: 17981505; PMCID: PMC3035105.
    37. Sergina NV, Rausch M, Wang D, Blair J, Hann B, Shokat KM, Moasser M. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature. 2007 Jan 25; 445(7126):437-41. PMID: 17206155; PMCID: PMC3025857.
    38. Hurria A, Hurria A, Zuckerman E, Panageas KS, Fornier M, D'Andrea G, Dang C, Moasser M, Robson M, Seidman A, Currie V, VanPoznak C, Theodoulou M, Lachs MS, Hudis C. A prospective, longitudinal study of the functional status and quality of life of older patients with breast cancer receiving adjuvant chemotherapy. J Am Geriatr Soc. 2006 Jul; 54(7):1119-24. PMID: 16866685.
      View in: PubMed
    39. Hurria A, Rosen C, Hudis C, Zuckerman E, Panageas KS, Lachs MS, Witmer M, van Gorp WG, Fornier M, D'Andrea G, Moasser M, Dang C, Van Poznak C, Hurria A, Holland J. Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study. J Am Geriatr Soc. 2006 Jun; 54(6):925-31. PMID: 16776787.
      View in: PubMed
    40. Hurria A, Goldfarb S, Rosen C, Holland J, Zuckerman E, Lachs MS, Witmer M, van Gorp WG, Fornier M, D'Andrea G, Moasser M, Dang C, Van Poznak C, Robson M, Currie VE, Theodoulou M, Norton L, Hudis C. Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient's perspective. Breast Cancer Res Treat. 2006 Aug; 98(3):343-8. PMID: 16541322.
      View in: PubMed
    41. Bhatt AS, Erdjument-Bromage H, Tempst P, Craik CS, Moasser M. Adhesion signaling by a novel mitotic substrate of src kinases. Oncogene. 2005 Aug 11; 24(34):5333-43. PMID: 16007225; PMCID: PMC3023961.
    42. Modi S, Currie VE, Seidman AD, Bach AM, Panageas KS, Theodoulou M, Moasser M, D'Andrea GM, Lake DE, Choi J, Norton L, Hudis CA. A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxane. Clin Breast Cancer. 2005 Apr; 6(1):55-60. PMID: 15899073.
      View in: PubMed
    43. Modi S, Seidman AD, Dickler M, Moasser M, D'Andrea G, Moynahan ME, Menell J, Panageas KS, Tan LK, Norton L, Hudis CA. A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancer. Breast Cancer Res Treat. 2005 Mar; 90(2):157-63. PMID: 15803362.
      View in: PubMed
    44. Dang CT, Dannenberg AJ, Subbaramaiah K, Dickler MN, Moasser M, Seidman AD, D'Andrea GM, Theodoulou M, Panageas KS, Norton L, Hudis CA. Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 1):4062-7. PMID: 15217939.
      View in: PubMed
    45. Mizenina OA, Moasser M. S-phase inhibition of cell cycle progression by a novel class of pyridopyrimidine tyrosine kinase inhibitors. Cell Cycle. 2004 Jun; 3(6):796-803. PMID: 15136770.
      View in: PubMed
    46. She QB, Solit D, Basso A, Moasser M. Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling. Clin Cancer Res. 2003 Oct 01; 9(12):4340-6. PMID: 14555504.
      View in: PubMed
    47. Huron DR, Gorre ME, Kraker AJ, Sawyers CL, Rosen N, Moasser M. A novel pyridopyrimidine inhibitor of abl kinase is a picomolar inhibitor of Bcr-abl-driven K562 cells and is effective against STI571-resistant Bcr-abl mutants. Clin Cancer Res. 2003 Apr; 9(4):1267-73. PMID: 12684394.
      View in: PubMed
    Mark's Networks
    Concepts
    Derived automatically from this person's publications.
    _
    Co-Authors
    People in Profiles who have published with this person.
    _
    Related Authors
    People who share related concepts with this person.
    _